MedPath

Trigonella, Foeniculum, Chichorium, Hornleum and Glycine in prevention of cancer-induced cachexia/anorexia

Phase 2
Conditions
Cancer-induced cachexia.
C80.0
C80.9
Registration Number
IRCT20180722040556N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

All adult patients (18 years and older) with advanced solid tumor malignancies (Stage 3-4) who encountered cancer-induced anorexia or weight loss (equal or greater than 5% of the previous weight before cancer diagnosis or within the last two months).
Cancer patients with serum creatinine < 2 mg / dl.
Cancer patients with serum total bilirubin < 2 mg / dl.
Patients haven't had any sign of dysphagia or gastrointestinal obstruction.
We have expected patients to be alive at least 3 upcoming months.
Patients who have received high doses of megestrol due to cachexia and anorexia simultaneously.

Exclusion Criteria

Patients who have undergone major surgery for the last 4 weeks.
Patients with a history of thrombophlebitis diseases.
Patients who have been taking systemic corticosteroid within the last 4 weeks or concurrently.
Patients who have cognitive impairment, psychiatric disorder or brain metastasis leading to cognitive impairment.
Patients who have diabetes, uncontrolled blood pressure or advanced heart failure (NYHA 4)
Patients who have consumed chronic alcohol.
Patients who are pregnant or breast-feeding.
Patients with a known hypersensitivity reaction to one of the plants in considered herbal combination

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of herbal combination consists of Trigonella, Foeniculum, Chichorium, Hornleum, and Glycine in the prevention of cancer-induced cachexia/anorexia. Timepoint: Baseline and 4 weeks later. Method of measurement: Edmonton criteria.
Secondary Outcome Measures
NameTimeMethod
Quality of life. Timepoint: Baseline and four weeks later. Method of measurement: Iranian Version of the EORTC QLQ.
© Copyright 2025. All Rights Reserved by MedPath